Altre lingue Administer Oyj

Azioni

ADMIN

FI4000513411

Mercato chiuso - Nasdaq Helsinki Altri mercati azionari 12:36:47 03/05/2024			Variaz. 5gg	Var. 1 gen.
2,5 ^EUR	0,00%		0,00%	+3,73%

11/04	Azioni Gerresheimer in calo sulle prospettive, ma contratti chiave confermati	RE
10/04	Administer Plc annuncia la nomina del Comitato di revisione contabile	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

BioXcel Therapeutics to Launch At-Home Trial of Potential Bipolar, Schizophrenia Agitation Treatment	22/04
Gerresheimer shares down on outlook, but key contracts confirmed	11/04
Resolutions of Administer Plc’s Annual General Meeting 2024 and the organising meeting of the Board of Directors	10/04
Administer Plc Announces Audit Committee Appointments	10/04
Administer Plc Announces No Dividend for the Financial Year Ended 31 December 2023	10/04
Administer Plc: Managers' Transactions, Herranen	05/04
Scotland's parliament considers assisted dying as poll shows support	28/03
Stoke Therapeutics Rises After Investigational Drug Shows Improvement in Dravet Syndrome Patients	26/03
Reinsurance Group in C$5.8 Billion Coinsurance Deal With Canada's Manulife	25/03
Administer Plc’s annual report for the year 2023 has been published	20/03
Administer Plc: Managers' Transactions, Herranen	19/03
Notice to Annual General Meeting of Administer Plc	18/03
Administer Oyj Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
Anima sees net outflows, while Fineco, Mediolanum post inflows	06/03
Insider information: Administer Group renews its strategy to ensure profitable growth – new financial targets and dividend policy	06/03
Administer Oyj Provides Earnings Guidance for 2026	06/03
Administer Plc: Growth continued strong, main focus in increasing profitability	06/03
UK chancellor hopes to reduce tax burden in "prudent" budget	03/03
Eagle Plains And Refined Metals Execute Option Agreement For The Dufferin Uranium Project	27/02
Arch Biopartners on Pre-IND Meeting With FDA to Repurpose Cilastatin as New Treatment to Prevent Acute Kidney Injury	27/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Administer Oyj

Azioni

ADMIN

FI4000513411

Altre lingue

Filtri